10-Q: Immunovant Reports Q2 2026 Results, Focuses on IMVT-1402

Immunovant Inc. reported its second-quarter 2026 financial results, highlighting increased research and development expenses and a continued net loss, while emphasizing the strategic focus on its lead asset, IMVT-1402.

Summary

• Immunovant reported a net loss of $153.2 million for the three months ended June 30, 2026, compared to a net loss of $120.6 million in the same period of 2025.
• Total operating expenses increased to $160.3 million from $127.2 million year-over-year, primarily driven by a rise in research and development (R&D) costs.
• R&D expenses grew by $41.4 million to $142.6 million, largely due to increased spending on clinical trials for IMVT-1402 across various therapeutic areas.
• General and administrative expenses decreased by $8.3 million to $17.7 million, attributed to lower personnel-related expenses and professional fees.
• The company ended the quarter with $797.8 million in cash and cash equivalents, but anticipates needing additional capital to fund its operations and business plan.
• Development of batoclimab has been discontinued to focus resources on IMVT-1402, with ongoing trials in Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, and Sjögren's disease.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant net losses, increased R&D expenses, and the ongoing need for substantial capital raises to fund operations and development.

Positives

• Positive preliminary results from the IMVT-1402 trial in difficult-to-treat rheumatoid arthritis (D2T RA) showed response rates of 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70.
• IMVT-1402 demonstrated deep, dose-dependent IgG reductions in a Phase 1 trial, with potential for approximately 80% IgG reductions and minimal off-target effects (albumin, LDL cholesterol).
• The company has a substantial cash balance of $797.8 million as of June 30, 2026, which is expected to fund operations to the potential commercial launch of IMVT-1402 in Graves' disease.
• The YpsoMate autoinjector, a convenient self-administered device, is being used for IMVT-1402 clinical trials.
• Learnings from the batoclimab program are being leveraged to inform the development of IMVT-1402.

Negatives

• A significant net loss of $153.2 million was reported for the quarter, an increase from $120.6 million in the prior year.
• Research and development expenses increased substantially by $41.4 million to $142.6 million, reflecting ongoing clinical trial costs.
• The company has not generated any revenue and does not expect to until regulatory approval and commercialization of IMVT-1402 or other product candidates.
• The discontinuation of batoclimab development after Phase 3 trials failed to meet primary endpoints in thyroid eye disease.
• The company acknowledges the need to raise additional capital, with potential adverse impacts on its operating plan if financing is not available.

Risks

• Clinical trials are expensive, time-consuming, and involve uncertain outcomes; delays or failures can occur at any stage.
• The company may not be able to obtain regulatory approval for IMVT-1402 or other product candidates.
• Future capital needs may not be met through equity offerings, debt financings, or collaborations, potentially requiring reevaluation of the operating plan.
• Disputes with HanAll regarding the future disposition of batoclimab could lead to arbitration or litigation.
• Macroeconomic conditions, including inflation, interest rates, and geopolitical tensions, may negatively affect the business and results of operations.
• Interim, preliminary, or topline data from clinical trials may differ from final data, potentially impacting business prospects and share price volatility.
• The company is dependent on third-party service providers, such as CROs, for clinical trials and manufacturing.

Future Outlook

The company expects its existing cash and cash equivalents of $797.8 million to be sufficient to fund its operating expenses and capital expenditure requirements, based on its current operating plan, through the potential commercial launch of IMVT-1402 in Graves' disease. However, potential expansions of development plans are being evaluated, which are not reflected in the current operating plan, and updated cash runway guidance will be provided if these plans are finalized.

Management Comments

• StockSavvy.ai notes that management expects to incur additional losses in the future to fund operations and product research and development, recognizing the need to raise additional capital.
• Management expects to continue to incur significant expenses at least for the next several years.
• The company anticipates that its general and administrative expenses will continue to support ongoing research and development activities.

Industry Context

StockSavvy.ai notes that the anti-FcRn market is competitive, with multiple companies researching and developing treatments for autoimmune diseases. Third-party estimates suggest a significant patient population could benefit from these therapies, with some already achieving multi-billion dollar sales, indicating substantial market potential.

Comparison to Industry Standards

• Competitor anti-FcRn programs have shown off-target effects such as reductions in albumin and increases in LDL cholesterol, which IMVT-1402 has demonstrated to have minimal impact on in early trials.
• Consistent evidence across the FcRn inhibitor class in Phase 2 and 3 trials indicates that deeper IgG reductions correlate with meaningful improvements in clinical outcomes.
• Immunovant's previous program, batoclimab, showed that IgG reductions of greater than or equal to 70% led to meaningfully better outcomes compared to reductions below 70%.

Legal Proceedings

• The company may be subject to various lawsuits, claims, and other legal matters from time to time, but as of June 30, 2026, it was not party to any material legal proceedings.

Related Party Transactions

• Services agreements with Roivant Sciences, Inc. (RSI) and Roivant Sciences GmbH (RSG) for development, administrative, and financial activities, with expenses recorded by the company totaling $0.3 million for the three months ended June 30, 2026.
• An information sharing and cooperation agreement with RSL, obligating the company to deliver financial statements and other information to RSL.

Stakeholder Impact

• Shareholders may experience volatility in stock price due to interim clinical trial data disclosures and the ongoing need for capital raises.
• Employees may be impacted by the company's financial performance and the strategic shift from batoclimab to IMVT-1402.
• Creditors and suppliers may be affected by the company's ability to secure future financing to meet its operational and development obligations.

Next Steps

• Expect to report top-line results from IMVT-1402 trials in Graves' disease (GD) in calendar year 2027.
• Expect to report top-line results from IMVT-1402 trial in myasthenia gravis (MG) in calendar year 2027.
• Further updates on the IMVT-1402 trial in D2T RA are expected in the second half of calendar year 2026.
• Expect to report top-line results from IMVT-1402 trial in Sjögren's disease (SjD) in calendar year 2028.
• Expect to report top-line results from IMVT-1402 trial in chronic inflammatory demyelinating polyneuropathy (CIDP) in calendar year 2028.
• Expect to report top-line results from IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) in the second half of calendar year 2026.

Key Dates

Recommendation

Immunovant presents a mixed picture with promising early data for IMVT-1402 and a strong cash position, but also significant net losses, increased R&D spending, and the failure of its previous lead candidate, batoclimab. The company's reliance on future capital raises and the inherent risks in late-stage drug development warrant a cautious 'hold' rating until further clinical data and financing clarity emerge.

Keywords

Immunovant, IMVT-1402, FcRn inhibitor, autoimmune diseases, clinical trials, Graves' disease, rheumatoid arthritis, biotechnology